glp-1 obesity drug supply news today medications are marketed to help you lose weight, but one may be better at it than the rest, according to a new meta-analysis from the UGA College of Pharmacy. Tirzepatide, better Poll: 1 in 8 Adults

Inhibition of SGLT-1 in the small intestine causes more glucose transport to the distal intestine and colon, resulting in greater fermentation of glucose to SCFAs by luminal bacteria and increased sustained release of GLP-1 in the distal intestine [174] (Fig

However, our survey of MedTech professionals challenges this notion

The potential side effects of the two drugs are very similar

The medicine company is headquartered in Indianapolis, Indiana

maintaining these weight loss results presents significant challenges, as the majority of patients are expected to experience an 80% rebound in lost weight within five years

Together, this multifactorial dilemma stipulates the necessity for the field to investigate novel pharmaceuticals and to extend the therapeutic utility of well-researched drugs already used in clinical practice